This Government Contract opportunity from Department Of Veterans Affairs was posted on May 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Acamprosate CA EC 333mg Tablet Manufacturing

Closed

Federal

Submission Closed05/28/2026, 07:30:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

Federal

6505--Dutasteride CapsulesThe Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP 36E79726R0029) for the procurement of Dutasteride Capsules to serve multiple federal agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted contract aims to secure a reliable supply source for Dutasteride 0.5MG capsules in both 30-count and 90-count bottles, with annual estimated usage of approximately 3,912 and 25,502 bottles respectively. The contract will be awarded to a single responsible offeror who can provide an uninterrupted supply and will have a one-year base period followed by four one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must supply the drug under the exact name on the label, with a unique National Drug Code (NDC) exclusive to the offeror. The contractor’s label must be the sole label on the product, with VA labels designed to adhere securely on top without obscuring important information such as barcodes, expiration dates, and lot numbers. Packaging requirements include safety caps that meet specific design criteria with a minimum bottle volume of 120cc and cylindrical shape to accommodate appropriate labeling sizes. The solicitation will be released in a commercial item format in accordance with FAR Part 12 around June 22, 2026, with proposals due by July 7, 2026. Interested parties should monitor SAM.gov for updates and submit offers electronically; efforts to obtain paper copies will not be accommodated. The contract specialist and primary point of contact for this procurement is Richard Mahario.

Nac Pharmaceuticals (36E797)

POSTED

DEADLINE

LEVOFLOXACIN TABLETThe contract pertains to the procurement of Levofloxacin tablets, identified by NSN/Part Number 6505-01-444-6632, with a purchase quantity of one unit under request number 7017178498. The solicitation, designated SPE2DP-26-T-3807, was issued by the Defense Logistics Agency on behalf of the Department of Defense with a posting date of June 15, 2026, and a response deadline set for June 22, 2026. This solicitation is categorized as a federal opportunity without specific set-aside conditions or NAICS code information provided. The contract will be performed within the United States, although exact location details are unspecified. The Defense Logistics Agency is managing the acquisition, and the solicitation details are accessible via a designated DIBBS URL for interested parties.

Defense Logistics Agency

POSTED

DEADLINE

Sole Source Total Parenteral Nutrition (TPN) solutions, including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid same-day delivery, seven days a weekThis contract involves the sole source procurement of Total Parenteral Nutrition (TPN) solutions, specifically including products such as TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid. The key requirement is for same-day delivery, seven days a week, ensuring continuous availability of these critical nutritional solutions. The solicitation number is HT941026N0069, with the notice posted on June 15, 2026, and a response deadline set for June 30, 2026. The contract falls under the NAICS code 325412, associated with pharmaceutical preparation manufacturing, and is issued by the Defense Health Agency located at Camp Pendleton, California. The place of performance is identified within Washington state, ZIP code 98431, indicating where the deliveries or contract services will be conducted. There is no set-aside designation for this procurement, reflecting an open competitive strategy or a direct sole-source justification. Primary and secondary points of contact are provided for further inquiries, with the primary contact being CHA-ON Gordon. The contract aims to support the Department of Defense’s ongoing medical and nutritional needs for personnel, emphasizing timely and reliable supply chain delivery for essential TPN products.

Defense Health Agency Hcd West

POSTED

DEADLINE

Custom Sterile Compounding of Total Parenteral Nutrition (TPN) FormulationsThe contract involves the manufacture and delivery of patient-specific, sterile Total Parenteral Nutrition (TPN) formulations, including branded products such as TrophAmin®, Plenamine, Nutrilipid®, and SMOF Lipid®. These formulations must be provided in volumes ranging from 1000 to over 3000 mL, with an absolute requirement for zero tolerance for deviations, ensuring strict adherence to quality and safety standards. This precision is critical given the nature of the products and their use in patient care. Administered by the Defense Health Agency Hcd West under the Department of Defense, the contract is categorized under NAICS code 325412, which pertains to pharmaceutical and medicine manufacturing. The contract is structured as a subcontract with a deadline for responses set for June 30, 2026. Performance is designated for an area identified by the zip code 98431. The contract underscores the importance of reliable, high-quality sterile compounding to meet defense health requirements with strict compliance to specifications and timelines.

Defense Health Agency Hcd West

POSTED

DEADLINE

Supply of Non-Substitutable Pharmaceutical IngredientsThis contract involves the supply of proprietary, branded pharmaceutical components including TrophAmin®, Plenamine, Nutrilipid®, and SMOF Lipid®, which are essential ingredients used in Total Parenteral Nutrition (TPN) formulations. The contract emphasizes full traceability and compliance with regulatory standards to ensure the safety and quality of these non-substitutable pharmaceutical ingredients. The procurement is managed by the Defense Health Agency Hcd West under the Department of Defense, reflecting the critical nature of these supplies for health services within defense operations. The solicitation was posted on June 15, 2026, with a response deadline set for June 30, 2026. The contract is classified as a subcontract under the NAICS code 325412, which pertains to pharmaceutical manufacturing. The place of performance falls within the 98431 zip code area, though specific city or state details are not disclosed. This contract supports the continued availability of specialized pharmaceutical components necessary for patient nutrition and care in military healthcare settings.

Defense Health Agency Hcd West

POSTED

2 days ago

DEADLINE

in 14 days

AI Contract Overview

The contract involves the full-scale manufacturing of Acamprosate Calcium Enteric Coated Tablets, each containing 333mg of the active ingredient, in compliance with FDA current Good Manufacturing Practice (cGMP) standards. The scope of work includes formulation development, tablet coating, rigorous quality control testing, and the timely release of production batches. The production process must meet stringent regulatory requirements to ensure product safety and efficacy. This subcontract is issued by Nac Pharmaceuticals, operating under the Department of Veterans Affairs, with the solicitation posted on May 14, 2026. Interested parties must submit their responses by May 28, 2026. The contract falls under NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. Specific details about the place of performance and points of contact are not provided, but the work is expected to adhere strictly to all regulatory and quality standards set forth by the FDA and the contracting agency.

General Info

Manufacture Acamprosate Calcium 333mg tablets under FDA cGMP, including formulation, coating, and testing.

Agency

Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

NAICS

325412 - Pharmaceutical Preparation Manufacturing View NAICS

Place of Performance

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedMay 14

subcontract

Response DeadlineMay 28

Deadline has passed

Submission Closed

05/28/2026, 07:30:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

Office AddressN/A

ContactsNo contact information available

Full Description

Full-scale production of Acamprosate Calcium Enteric Coated Tablets (333mg) under FDA cGMP standards, including formulation, coating, quality control, and batch release.